5α-androstanyl-3α,17β-diether | 876475-07-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α-androstanyl-3α,17β-diether
• 英文别名: Androstanediol；Dehydroepiandrosteron；Androstan-3,17-diol；3alpha,17beta-Dihydroxy-5alpha-androstane；10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 876475-07-9
• 化学式: C₁₉H₃₂O₂
• 分子量: 292.462
• InChiKey: CBMYJHIOYJEBSB-UHFFFAOYSA-N

物化性质

• 沸点：
  415.0±18.0 °C(Predicted)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,10,15-triphenyl-20-(2,3,4,5,6-pentafluorophenyl)porphyrinato zinc(II) 、 5α-androstanyl-3α,17β-diether 在 sodium hydride 作用下， 以 further solvent(s) 为溶剂， 以19%的产率得到
  参考文献：
  名称：

  Distance Dependence of Photoinduced Electron Transfer in Metalloporphyrin Dimers

  摘要：

  To study the dynamics and mechanism of intramolecular photoinduced electron transfer (PET) reactions, a series of (Zn-II-Fe-III), meso-tetraarylmetalloporphyrin dimers were synthesized and the kinetics of their PET reactivity was measured. Molecular building blocks were prepared by selective nucleophilic aromatic substitution of a para fluorine on tetraarylporphyrins containing a single pentafluorophenyl group. This synthetic approach allows a wide variety of systematic modifications such as type and length of spacer, metal center, and redox-potential difference between donor and acceptor. The edge-to-edge distance between the two porphyrins varies from 14.4 to 27.3 Angstrom. Into a symmetric dimer, with two identical porphyrins covalently linked by a rigid partly saturated bridge, one zinc(II) and one iron(III) can be inserted. From measurements of fluorescence lifetimes the rate constants for PET from the electronically excited state of the zinc porphyrin to the bis(imidazole)iron porphyrin cation were evaluated. The electron-transfer rate decreases by a factor of only 165 when the distance increases by 13 Angstrom. This small decrease is indicative of a surprisingly weak attenuation of the electronic coupling with distance.

  DOI：

  10.1021/jp991766s
• 作为产物：
  描述：

  3ξ-hydroxy-(5ξ)-androstan-17-one 在 甲醇 、 Ru-MACHO 、 水 、 potassium hydroxide 作用下， 以91 %的产率得到5α-androstanyl-3α,17β-diether
  参考文献：
  名称：

  使用甲醇进行功能化合物的通用和选择性均相钌催化转移氢化、氘化和甲基化

  摘要：

  有机合成和能源技术中甲醇的催化增值对于基础研究和工业应用来说都是有趣且重要的。特别是，它作为氢、氘和甲基源用于选择性还原和氘化反应以及获得N-甲基化产物是非常理想的，并且可以被认为是放大转移氢化和C1化学的潜在方法。在这里，我们报道了均相 Ru-MACHO 配合物催化不同官能化化合物（如酮、醛、炔烃、烯烃、亚胺、偶氮苯和硝基化合物）的转移氢化以及N的脱氧使用甲醇作为负担得起的氢供体和溶剂的氧化物衍生物。这种基于钌的策略已被证明对于合成先进氘标记化合物的氘化过程非常方便，包括克级合成氘代药物，如d-氯哌斯汀、d-布克利嗪、d-苯地亚明、d-莫达非尼和d -Adrafinil 使用 CD 3 OD。此外，还展示了甲醇作为C1源用于制备N-甲基化产物的应用。最后，对这种钌催化的转移氢化和氘化方案进行了动力学和机理研究。

  DOI：

  10.1016/j.jcat.2023.06.035

文献信息

• Materials free of endocrine disruptive activity
  申请人：Bittner, George

  公开号：EP1897907A1

  公开（公告）日：2008-03-12

  The present invention describes chemicals that have certain properties which cause them to be free or substantially free from endocrine disruptive activity. As a result, the chemicals are useful in producing plastic materials that may be used in products which are exposed to individuals in which endocrine disruptive activity is particularly disadvantageous, such as baby bottles, baby toys, food containers, medical containers, animal cages and medical products. The chemicals may also be useful as food additives which are used in food products that are ingested by individuals in which endocrine disruptive activity is particularly disadvantageous, such as newborns or the physically infirm.

  本发明描述了具有某些特性的化学品，这些特性使它们不含或基本上不含内分泌干扰活性。因此，本发明的化学品可用于生产塑料材料，这些材料可用于暴露于内分泌干扰活性特别不利的人的产品中，如婴儿奶瓶、婴儿玩具、食品容器、医疗容器、动物笼和医疗产品。这些化学品还可用作食品添加剂，用于内分泌干扰活动对新生儿或体弱者等特别有害的人群摄入的食品中。
• MATERIALS FREE OF ENDOCRINE DISRUPTIVE ACTIVITY
  申请人：Bittner George

  公开号：US20080064795A1

  公开（公告）日：2008-03-13

  The present invention describes chemicals that have certain properties which cause them to be free or substantially free from endocrine disruptive activity. As a result, the chemicals are useful in producing plastic materials that may be used in products which are exposed to individuals in which endocrine disruptive activity is particularly disadvantageous, such as baby bottles, baby toys, food containers, medical containers, animal cages and medical products. The chemicals may also be useful as food additives which are used in food products that are ingested by individuals in which endocrine disruptive activity is particularly disadvantageous, such as newborns or the physically infirm.
• Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids
  申请人：Petroni Anna

  公开号：US20100317639A1

  公开（公告）日：2010-12-16

  A monoester of a family of steroids with a C 16 -C 24 fatty acid for use as a medicament is disclosed. Particularly the monoester of 5α-androstan-3α,17β-diol with a C 16 -C 24 fatty acid is disclosed, such as preferably linoleic acid in all its isomeric forms. The medicament is capable to reduce the accumulation of cholesterol esters, reducing the ACAT enzyme (acyl-coenzyme A: cholesterol acetyltransferase) effect so that monoesters are used for the manufacture of a medicament for treating adrenoleucodistrophy, Alzheimer's disease and arteriosclerosis.
• [EN] ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF)<br/>[FR] PRÉPARATION INTRAVEINEUSE CONTENANT DE L'ISTAROXIME POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE AIGUË (ICA)
  申请人：WINDTREE THERAPEUTICS INC

  公开号：WO2020180356A9

  公开（公告）日：2020-11-12

  [EN] Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.
  [FR] L'invention concerne des compositions destinées à la perfusion intraveineuse d'istaroxime ou d'un métabolite de l'istaroxime, chez des patients humains souffrant d'insuffisance cardiaque. De même, l'invention concerne des méthodes permettant une perfusion de longue durée d'istaroxime ou de ses métabolites, chez des individus atteints d'insuffisance cardiaque. En particulier, certaines méthodes selon l'invention comprennent la perfusion d'istaroxime ou d'un métabolite de celle-ci, sur une durée supérieure à six heures en vue d'améliorer la relaxation cardiaque sans déclencher d'événements arythmiques chez un individu souffrant d'insuffisance cardiaque. D'autres méthodes comprennent l'administration d'istaroxime jusqu'à ce que certains seuils de concentration plasmatique des métabolites de l'istaroxime soient atteints. L'invention concerne également des métabolites de l'istaroxime qui ont une capacité à activer de façon sélective la SERCA2a.
• [EN] SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF<br/>[FR] ENDUITS DE SURFACE, DISPOSITIFS IMPLANTABLES COMPRENANT DES PROMÉDICAMENTS STÉROÏDIENS DIMÈRES ET LEURS UTILISATIONS
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021005417A1

  公开（公告）日：2021-01-14

  The disclosure features surface coatings formed from dimeric steroid prodrugs for the extended delivery of a drug from a surface, and for the treatment of a disease or condition. Also provided herein are drug depots formed from dimeric steroid prodrugs for the extended delivery of a drug for use in combination with implantable medical devices. Said dimeric steroid prodrugs are represented by the formula D1-L-D2, wherein D1 and D2 are independently a steroid radical and L is a linker covalently linking D1 to D2.